Alembic Pharmaceuticals Ltd.
Fundamentals
- Market cap
- ₹15,165 cr
- P/E
- 22.47×
- ROE
- 11.24%
- Debt / equity
- 0.23
- Div yield
- 1.54%
- 52-week range
- 635.80 — 1107.90
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 7 notes on Alembic Pharmaceuticals Ltd.
June 2026
- 19 Jun 26 · 1:50 PM IST Lead Lead · Mid cap
Alembic eyes $259M cancer market with tentative US nod for Binimetinib
Sole first applicant with Paragraph IV, Alembic qualifies for 180-day generic exclusivity on a melanoma and NSCLC drug. This is its largest single-product opportunity this year.
- 12 Jun 26 · 12:47 PM IST Brief Brief · Mid cap
Alembic gets USFDA nod for generic Retin-A — but market is small
The $76 million US market for Tretinoin Cream is less than 1% of Alembic's annual revenue, making this a routine pipeline addition.
- 11 Jun 26 · 12:48 PM IST Lead Lead · Mid cap
Alembic lands 180-day exclusivity shot on $91m US cancer drug
Tentative USFDA approval for the generic of Bayer's Vitrakvi makes Alembic the sole first applicant. The US market for the oncology drug is $91 million.
- 06 Jun 26 · 4:06 PM IST Brief Brief · Mid cap
Alembic takes 45% in new Canadian pharma JV with Difgen Holdings
Alembic Pharmaceuticals is entering the Canadian market via a joint venture but won't say how much it's spending.
- 05 Jun 26 · 10:53 AM IST Brief Brief · Mid cap
Alembic lands generic Haldol approval, but the US market is tiny
Final USFDA clearance for Haloperidol Tablets adds to a 240-product pipeline. The market it addresses is less than 3% of Alembic's revenue.
May 2026
- 22 May 26 · 11:00 AM IST Lead Lead · Mid cap
Alembic lands US launch for generic Synthroid into a $1.87bn market
Final USFDA approval lets Alembic sell immediately into the biggest thyroid-drug market in the US. The addressable market is more than double the company’s annual revenue.
- 21 May 26 · 3:31 PM IST Brief Brief · Earnings · Mid cap
Alembic sets FY27 revenue growth target at low double digits
Q4 FY26 conference call transcript confirms guidance for low double-digit revenue growth, R&D spend of ₹750-800 crore, and margin improvement.